Recently, the Clinical Laboratory Center of the National Health Commission (NCCL) released the results report of the "2023 Tumor Circulating Cell-free DNA (ctDNA) Gene Mutation High throughput Sequencing Quality Assessment (NCCL-I-32-2023)". Shanghai Epione Medlab, a subsidiary of Dunwill Medical, successfully passed with full marks once again!

Tumor Circulating Cell-free DNA (ctDNA) Gene Mutation High Throughput Sequencing Quality Assessment is an important means to ensure the quality of testing in various clinical laboratories. It can test the ability of participating laboratories to perform high-throughput sequencing of ctDNA gene mutations, identify common problems in testing, and identify special problems in certain laboratories, thereby promoting the improvement of laboratory testing levels.

A total of 241 laboratories from 25 provinces (cities, autonomous regions) participated in this proficiency test. Among them, 229 laboratories that reported results on schedule and passed nucleic acid extraction had an overall qualitative testing qualification rate of 82.97% (190/229), with a full score laboratory accounting for 74.23% (170/229). Epione Medlab reported the results of this assessment using the "Tumor Precision Drug 70 Gene and MSI Joint Testing" independently developed by its parent company, Dunwill Medical. The combination of tumor precision medicine 70 gene and MSI detection covers major cancer-related target genes and microsatellite instability, including lung cancer, colorectal cancer, gastrointestinal stromal tumors, and cholangiocarcinoma. It comprehensively identifies pathogenic variants and accurately evaluates microsatellite instability status to meet a wide range of clinical needs.

Epione Medlab passing with a full score, not only demonstrates a high level and extremely stable tesing ability, but also demonstrates excellent standardization and professionalism in clinical tumor testing. Epione has always carried out standardized management with high standards, established a sound quality system, and standardized sample quality control processes, providing scientific and accurate data for diagnosis and precision treatment. It also proves that the liquid biopsy products of Epione have been recognized by national authoritative institutions for their standardization and reliability in the entire process like quality control, nucleic acid extraction, high-throughput sequencing, and bioinformatics analysis, and their detection capabilities have reached the leading level in the industry.

In the future, Epione Medlab will continue to strictly manage and strive to provide customers with high-quality products and services, thereby creating greater value for customers.